Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t think they will have to cover the shorts.
If anything they will short more on the 23rd.
The split new price could be about $8 a share.
The shorts will hit it again to try to get it below $2
Then they may think about covering
There should be about 4.88 million shares after the split.
That is about the amount of shares when i 1st bought shares maybe 7 million shares.
JAGX kept selling shares into the market diluting shares. They will do it all over again if history repeats.
If they do a RS won’t it shake out all the short positions after the split and with phase 3 PR should pop huge!!!! Especially with all the craze hot meme stocks???
FFIE saved the day…
How do you think it will fare next week, before the split? Drop some more? More selling, more buying? The r/s 1:60 is horrible for any stock, but this has a big catalyst coming. Honestly, i don't know what to do on monday.
This management team at JAGX has hurt alot of investors through the years
I just sold my last 10,000 shares @ .14 that i paid 67 cents for but because i loaded way up around 10 cents that i made a profit on JAGX to the point that these were free trading shares.
If there is one thing i do not like it is the brutal reverse split.
This stock is brutal to the shareholders
I wish everyone the best of luck here.
I know how you feel...been burned like that enough... but at least they have a big hopeful catalyst ahead...many times a company has absolutely nothing in the works when they split....but not the case with JAGX...I hope it ends well for all involved.
Oh, i'm sure that's the plan, i mean, there's no other explanation for it. It's just a massive headache atm...
You never know DanDosh they might just do that directly after the split...it might be a strategic move so institutions might take interest.
At least it's a nice price to buy right now, for those that still have $ left aside to gamble the PIII catalyst. I think it will bounce a bit back, till may 23, based on this logic. Right?! Or maybe it's just my stupid copium, that got me burned so many times. God dammit...
They want to make it attractive to investors.... They'll announce PIII results, positive, at ASCO, but first they needed a stock with a price that's more attractive. It's a shitty situation, i had hoped they wouldn't do this, but they did nonetheless.
I figured they would at least wait until July considering they had until August 13th 2024.
I'm so pissed right now to sell at loss this pos stock, but the only saving will still be those damn PIII results. FFS. I should have listened when people said this stock murders its stockholders...
Split won't happen until next Thursday May 23rd
Yeah they announced it on their website before filing it.
https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-inc-announces-reverse-stock-split
Apparently, your dream turned into a nightmare.
Not finding that announcement on EDGAR or OTC markets...can you post the link?
Well now, thats a pretty frigging ugly to do on a Friday night..
Hope the next thing they say is the PH 3 results to help absorb the blow from the r/split or this will be a short seller target..
What the Sam hell fuck happened ???!!!!
RS 1:60 announced
did the PH 3 fail?? or is this a FRIDAY headfake??
what in the heck is happening??? 14 cents
I agree the longer the consolidation, the better, but here it's a matter of days ("imminent", whatever it means in the CEO's head), or two weeks max, till may 31-june 4 (asco). Anything beyond that and no one will hold this anymore. Even for two weeks, i would be surprised if it holds current levels, without any external input... Problem with waiting is you don't really know when they'll drop the big news, and you'll be left out. If they didn't used the term "imminent", i too think i would have waited a bit more, closer to ASCO. But i bought at 0.27 and let it sit, i've been burned before trying to time such things...
I'm using the 3rd when it peaked and lower highs started. So its in day 11 of the 'consolidating' its gains..
But for a 'good' consolidation? I expect to see 5 weeks min to shake folks out.. and I expect to see some
heavier volume days indicating those considering selling, threw in the proverbial towel and the flush out is over.
Does it mean its going to happen like that with this one? Will only know once its 'over' and the next leg up commences.
Heck it may hold at 26 cents +.. TBD'd..
disclaimer: own none, and don't like the activity today enough to take a run at a trade.
But will own some hopefully before the 'imminent' PR occurrs. just to see what happens.
And yes, would like to see from a 'selfish' standpoint, 21-23. And for those not selling, just holding, it won't matter what it does till the PR
is released.. cause the expectation is for higher.. when its said and done
Personally, i think it's been consolidating since 7th of May, between .25 and .3, much of it between .26 and .28. If it drops below 0.25, to the 0.21 - 0.23 range, i would start to worry... it would suck. But i've seen the stock reaction when it dropped briefly (twice) to ~0.24, it got immediately bought up, so i'm not too worried in the short term.
No idea how deep it MIGHT drop, or if it even will. Heck, it might just run flat here at 26-27. But after these kinds of runs, some CONSOLIDATION is NEEDED to set a new base price...
But after this much momentum to get to this price level?? and the expectation of 'more'??
TBD'd what happens between now and the next 'imminent' PR..
no big drop buy when scared
There won't be a big drop soon, without bad news, just like there won't be a big run up without good news. It's just consolidation and trading. It won't drop much because there's demand in anticipation of PIII results. Zoom out the chart, if you feel unsure, you'll see.
That’s how I feel. Afraid from big drop soon
Who knows it’s 50/50 worth the gambling$$$ Thank you!
Thank you so much! And good luck$$$
we are currently 367% off the lows in February, almost the time people bailed on the stock. We had a huge 255% move off the bottom in a few days, I wonder if we can get a 500-1000% move off news 🥰
.64c then $1.15 then $3.05, then moon
Sold yesterday at 28.27... chart is showing some 'caution' signs. Its ran hard, is overdue for a good shake out, and
after the nice run it made, going to be interesting to see if the longer it 'sits' flat if holders start to get impatient and start locking in
their gains. Especially IF it starts to show thats happening and it becomes self feeding into a pullback.
A friend and I have been trading shares the last few days in a take what it gives approach. He has gotten
a bit enthusiastic expecting the buy low sell high is going to keep working out. And it might if he takes what it gives
vs 'seeing' how much he can get by just holding out for a little more.
But my primary momentum indicator has gone negative, and another one is flashing a warning that
it too could turn negative. But thats to be expected in a CONSOLIDATION phase.
Too early to tell if thats whats going on, but if it does get a foothold, going to be interesting
to see what the share price does (run flat, pullback some TBD'd)
Disclaimer: own none, traded shares 2x now after the big run up.. Looking to try again today..
But being patient not to trap myself..
So AMC THEN FFIE if it’s going alphabetical order we should be up next lol
forthcoming adjective (SOON)
happening soon: We have just received the information about the forthcoming conference.
Can’t wait till this is a UPDATED PR!!!!
Jaguar Health (JAGX) Reports Majority of Subjects in Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
December 11, 2023 8:32 AM
Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar) family company, today announced that a majority of subjects in the company's placebo-controlled pivotal Phase 3 OnTarget trial for prophylaxis (prevention) of diarrhea in adult cancer patients receiving targeted therapy with or without standard chemotherapy chose to continue on to Stage II of the two-stage trial.
After completing the Stage I double-blind, placebo-controlled primary prophylactic treatment phase of OnTarget, subjects had the option to remain on their blinded assigned treatment arm and reconsent to enter into the Stage II extension phase.
"We are very pleased that a majority of subjects chose to continue on to Stage II while recognizing that their requirement to remain blinded would continue," said Lisa Conte, Jaguar's president and CEO. "We are deeply committed to all patients who participated in the OnTarget trial. We view them as key stakeholders and we thank them for their support and participation in this study."
Stage II of the trial has concluded. Inclusion of Stage I data and Stage II data, with success, is required in the supplemental NDA filing of crofelemer to add the indication for prophylaxis of diarrhea in cancer patients receiving targeted therapy with or without standard chemotherapy.
"Since all patient data will be included in the final locked database, we will remain blinded and will announce the comprehensive results of the full trial, including Stage II results, rather than proceeding with the original plan of announcing top line results for Stage I only. We expect the full trial results to be available in the first quarter of 2024," Conte said. "The clinical trial database includes patients with multiple solid tumor types, and the trial allowed the inclusion of 24 different targeted therapies, including multiple important mechanisms of action for targeted therapy drugs."
OnTarget is a first-of-its-kind, 24-week (two 12-week stages) clinical trial with a primary endpoint based on patient-reported outcomes that address the highly neglected and unmet burden of cancer therapy-related diarrhea, an indication Napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic and/or episodic debilitating diarrhea (loose and/or watery stools), urgency, bowel incontinence and abdominal pain and discomfort.
Diarrhea is a common side effect of targeted therapies and new treatments are needed. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.1 The OnTarget study is testing whether the company's plant-based prescription drug crofelemer (versus placebo) can prevent (or substantially reduce) diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies (that are associated with diarrhea in at least 50% of patients) is initiated.
"We are excited as any stakeholder to see the results. We own the expectation we set that data would be available in November 2023. We have to respect and abide by the requirements and Standard Operating Procedures of our third-party service providers and work with them as we meet GCP (Good Clinical Practice) requirements, particularly when conducting a complex global Phase 3 clinical trial," Conte said. "These service providers have important quality control procedures that take time and somewhat expand as the data analysis process progresses. We are working with all vendors that are critical to ensure the integrity of the data. Jaguar and Napo personnel continue to remain blinded to the study results at this time."
Napo's abstract outlining the design of the OnTarget trial, the importance of patient reported outcomes, and the neglected medical need of CIOB was the subject of a poster presentation on December 7, 2023 at the San Antonio Breast Cancer Symposium (SABCS). More than two dozen leading patient advocacy groups provided powerful voices at events hosted by Napo, highlighting the neglected need of mitigating diarrhea in patients receiving cancer therapies, and expressing strong support for the company's focus on patient quality of life.
$1.00+ will come. Management has faith in P3. P2 was great, already approved for animals we are looking very good.
If all the “penny stocks” are going MOASS with no new news and just speculative plays but WE ARE FIGHTING CANCER THAT $1 should be attainable and waaaay more. Just saying…
Even the AI who smarter than me atleast agrees it will go to a $1 soon
https://coincodex.com/stock/JAGX/price-prediction/
But first.... .40 today.😁
The at 5 day BULL FLAG LOOKONG GOOD ONLY TIME NOW TOLL WE POP!
Yeah I dumped to early today I wanted to vomit after I saw it move thought after half it would tank but oh no VOLUME short interest rocketed that bad boy past $2!!!!
This is about to pop to .50+
I know the feeling. GL
Followers
|
157
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6559
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |